Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· October 20, 2026

Salesforce Signs Definitive Agreement to Acquire Braze

View original at finance.yahoo.com
Salesforce Signs Definitive Agreement to Acquire Braze SAN FRANCISCO & NEW YORK, October 20, 2026--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, today announced it has entered into a definitive agreement to acquire Braze (NASDAQ: BRZE), a leading customer engagement platform, for approximately $5.66 b…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Braze shipped at the fastest pace in its history this past year; it will continue building as Braze and investing in its community of customers and partners, and Salesforce's platform will help it innovate faster.

    60% confidence
  • Braze's platform powers trillions of messages and journey actions each year.

    60% confidence
  • AI is raising the bar for marketers, who now need agentic solutions that understand customers, make decisions, and act in real time; Salesforce is moving to lead that shift through organic innovation and acquisitions meeting its M&A framework.

    60% confidence
  • Following close, Braze's real-time engagement and AI decisioning capabilities are expected to complement all four layers of Salesforce's architecture and strengthen Marketing Cloud's cross-channel personalization at the scale needed to reach hundreds of millions of people.

    60% confidence
  • Braze was built to turn live customer behavior into personalized engagement at scale, and combining it with Salesforce Marketing Cloud, CRM, and Data 360 will deliver a wow moment in every customer interaction.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
Salesforce Signs Definitive Agreement to Acquire Braze — Source | Via News | Via News